Buscar
Madrigal Pharmaceuticals Inc
MDGLAñadir a la lista de seguimiento
460.640USD
-32.470-6.58%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
10.61BCap. mercado
PérdidaP/E TTM
Más Datos de Madrigal Pharmaceuticals Inc Compañía
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Información de Madrigal Pharmaceuticals Inc
Símbolo de cotizaciónMDGL
Nombre de la empresaMadrigal Pharmaceuticals Inc
Fecha de salida a bolsaFeb 06, 2007
Director ejecutivoSibold (Bill)
Número de empleados528
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 06
Dirección200 Barr Harbor Drive, Suite 400
CiudadWEST CONSHOHOCKEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19428
Teléfono14043809263
Sitio Webhttps://www.madrigalpharma.com/
Símbolo de cotizaciónMDGL
Fecha de salida a bolsaFeb 06, 2007
Director ejecutivoSibold (Bill)
Ejecutivos de Madrigal Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Director
Director
169.12K
+2.37%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
21.75K
+2.09%
Mr. Raymond Cheong, M.D., Ph.D.
Mr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
4.21K
+43.16%
Mr. Kenneth M. (Ken) Bate
Mr. Kenneth M. (Ken) Bate
Independent Director
Independent Director
1.91K
--
Ms. Shannon Kelley
Ms. Shannon Kelley
Executive Vice President, Chief Legal Counsel
Executive Vice President, Chief Legal Counsel
437.00
-280.09%
Ms. Carole A Huntsman
Ms. Carole A Huntsman
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
428.00
-64.02%
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Director
Director
--
--
Mr. James M. Daly
Mr. James M. Daly
Independent Director
Independent Director
--
--
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Bill Sibold
Mr. Bill Sibold
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Director
Director
169.12K
+2.37%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
21.75K
+2.09%
Mr. Raymond Cheong, M.D., Ph.D.
Mr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
4.21K
+43.16%
Mr. Kenneth M. (Ken) Bate
Mr. Kenneth M. (Ken) Bate
Independent Director
Independent Director
1.91K
--
Ms. Shannon Kelley
Ms. Shannon Kelley
Executive Vice President, Chief Legal Counsel
Executive Vice President, Chief Legal Counsel
437.00
-280.09%
Ms. Carole A Huntsman
Ms. Carole A Huntsman
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
428.00
-64.02%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Madrigal Pharmaceuticals Inc?
Los cinco principales accionistas de Madrigal Pharmaceuticals Inc son: Dr. Paul A. Friedman, M.D.
¿Cuántas instituciones poseen acciones de Madrigal Pharmaceuticals Inc (MDGL)?
A fecha de 2026Q1, 750 instituciones poseen acciones de Madrigal Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 24.02M, lo que representa el 104.16% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -163523.00.